As previously mentioned, the first drug in the SSRI class to be developed and marketed was zimeldine, but unfortunately several cases of Guillain-Barré syndrome were associated with the use of the drug and led to withdrawal from the market in 1983.
As previously mentioned, the first drug in the SSRI class to be developed and marketed was zimeldine. Unfortunately several cases of Guillain-Barré syndrome were associated with the use of the drug. Unfortunately several cases of Guillain-Barré syndrome were led to withdrawal from the market in 1983.